#Incretin mimetics
GLP-1, GIP, glucagon receptor agonists.
Tirzepatide: 10-year CVD risk in SURMOUNT-1
Post-hoc SURMOUNT-1 analysis: tirzepatide 15 mg cut predicted 10-year CVD risk by 1.92 pp at 72 weeks, widening to a 5.15 pp gap over placebo at three years.
Oral GLP-1 drugs for obesity, no diabetes
A 2026 network meta-analysis of nine trials ranks oral semaglutide and orforglipron as top performers for weight loss in adults with obesity without diabetes.
Zepbound versus obesity pills
Zepbound still has strong direct trial evidence as oral obesity medicines add useful, but not automatically superior, options.
Tirzepatide and heart events: BMJ study
A 2026 BMJ cohort linked tirzepatide to fewer cardiovascular events than sitagliptin, but the result remains observational.
Tirzepatide for sleep apnea
Tirzepatide reduced sleep-apnea severity in adults with obesity, but the evidence does not make it a universal substitute for CPAP.
Tirzepatide vials: what the label says
Mounjaro and Zepbound use single-dose vials. Pooling drug between vials is not described in either label. Here is what the prescribing information says.
Lilly and Resilience: $750M GLP-1 capacity
Eli Lilly and contract manufacturer Resilience announced a $750M Cincinnati expansion adding 400 jobs to GLP-1 injectable production. What it means for supply.
Peptide blood tests before and after
What a before and after blood panel can show around retatrutide, hCG or Semax, what it cannot, and why interpretation belongs with a clinician.
GLP-1 and GIP: a short incretin history
Incretins went from a failed 1906 diabetes experiment to GLP-1 and GIP drugs. Here are the dates, the discoveries, and where the evidence thins out.
Tirzepatide and a rash: one case report
A 2026 JAAD case report links a year of tirzepatide to a widespread rash that cleared when the drug stopped. One patient is not a risk rate.
Why weight loss stalls on tirzepatide
A weight loss plateau is the expected shape of the tirzepatide curve, not a failure. Here is what the trials show and where retatrutide really stands.
Japan tirzepatide dispensing and dose mix
Japan's claims data show 86.2% of tirzepatide kits dispensed outside medical institutions, with higher strengths nearly doubling their share in ten months.